Pulmonary administration of chemically modified insulin
First Claim
Patent Images
1. A dry powder composition for pulmonary administration, said composition comprising a conjugate of insulin covalently coupled to one or more molecules of polyethylene glycol, wherein said powder (i) is characterized by having an emitted dose value of at least about 50% and (ii) when administered to a subject by inhalation, sustains elevated blood levels of insulin in said subject for at least about 6 hours post administration.
6 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides active, hydrophilic polymer-modified derivatives of insulin. The insulin derivatives of the invention are, in one aspect, suitable for delivery to the lung and exhibit pharmakokinetic and/or pharmacodynamic properties that are significantly improved over native insulin.
139 Citations
44 Claims
- 1. A dry powder composition for pulmonary administration, said composition comprising a conjugate of insulin covalently coupled to one or more molecules of polyethylene glycol, wherein said powder (i) is characterized by having an emitted dose value of at least about 50% and (ii) when administered to a subject by inhalation, sustains elevated blood levels of insulin in said subject for at least about 6 hours post administration.
Specification